These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36226229)

  • 21. Retracted: Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information.
    Omaer A; Aldosari FM; McGlamery E; Alrashed S; Wool S; Fazel MT
    J Clin Pharm Ther; 2022 Jan; 47(1):i. PubMed ID: 34254331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Pozo-Rosich P; Ailani J; Ashina M; Goadsby PJ; Lipton RB; Reuter U; Guo H; Schwefel B; Lu K; Boinpally R; Miceli R; De Abreu Ferreira R; McCusker E; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Sep; 402(10404):775-785. PubMed ID: 37516125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
    Garland SG; Smith SM; Gums JG
    Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
    [No Abstract]   [Full Text] [Related]  

  • 28. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
    Tepper SJ; Sheikh HU; Dougherty CO; Nahas SJ; Winner PK; Karanam AK; Blumenfeld AM; Abdrabboh A; Rasmussen S; Weiss JL; Ailani J
    Headache; 2022 Apr; 62(4):420-435. PubMed ID: 35137404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxins for the prevention of migraine in adults.
    Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.
    Cohen F; Yuan H
    Ther Clin Risk Manag; 2022; 18():447-456. PubMed ID: 35493707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Pharmacotherapy for Episodic Migraine.
    Chan C; Goadsby PJ
    CNS Drugs; 2019 Nov; 33(11):1053-1071. PubMed ID: 31556018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
    Sevivas H; Fresco P
    Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.